

Clovis Oncology, Inc.  
Form 8-K  
November 16, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): November 16, 2015**

**Clovis Oncology, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
**of incorporation)**

**001-35347**  
**(Commission**  
**File Number)**

**90-0475355**  
**(I.R.S. Employer**  
**Identification No.)**

**2525 28<sup>th</sup> Street, Suite 100**  
**Boulder, Colorado**

**80301**

**(Address of principal  
executive offices)**

**(Zip Code)**

**Registrant's telephone number, including area code: (303) 625-5000**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On November 16, 2015, Clovis Oncology, Inc. (the Company) hosted a conference call to discuss a regulatory update related to its NDA filing for rociletinib. A copy of the conference call transcript is attached as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 of Form 8-K and the information incorporated by reference herein, including Exhibit 99.1 attached hereto, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 8.01 Other Events.**

On November 16, 2015, the Company issued a press release providing a regulatory update related to its NDA filing for rociletinib. A copy of the press release is attached as Exhibit 99.2 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Number and Description

99.1 Conference Call Transcript, dated November 16, 2015.

99.2 Press Release, dated November 16, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CLOVIS ONCOLOGY, INC.**

November 16, 2015

By: /s/ Erle T. Mast

Name: Erle T. Mast

Executive Vice President and Chief Financial

Title: Officer

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Conference Call Transcript, dated November 16, 2015.
99.2	Press Release, dated November 16, 2015.